Allergan Sues Imprimis, Prescriber’s Choice, Sincerus Florida

September 8, 2017: By Jon Swedien

legal issuesAllergan filed lawsuits Sept. 7 against Imprimis Pharmaceuticals, Prescriber’s Choice, and Sincerus Florida, claiming they are illegally selling unapproved new drugs.

Allergan filed one complaint against Imprimis and one against both Prescriber’s Choice and Sincerus in the US District Court for the Central District of California.

Allergan’s complaints allege that the companies are illegally manufacturing and selling unapproved new drugs under the false guise that they are engaged in lawful compounding. Allergan also claims the three are engaging in false and misleading advertising and promotion of unapproved new drugs.

In a prepared statement, Allergan said it was taking this step because companies such as Allergan have a duty to put the safety of their patients first and it believes the three defendants are putting patients and physicians at risk.

Imprimis and Sincerus are US FDA-registered 503B outsourcing facilities. Prescriber’s Choice is a management company that assist physicians.

Allergan also claims that all three defendants are in violation of the Lanham Act, which protects against trademark infringements and state laws.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022